As of December 31, 2025, Definium Therapeutics (DFTX) had cash, cash equivalents and investments of $411.6 million compared to $273.7 million as of December 31, 2024. Based on the Company’s current operating plan and anticipated milestones, the Company believes that its cash, cash equivalents and investments as of December 31, 2025 will be sufficient to fund the Company’s operations into 2028.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial
- Is MNMD a Buy, Before Earnings?
- Definium Therapeutics initiated with an Outperform at Wolfe Research
- Psychedelic: Exclusive talk with nonprofit organization MAPS
- Psychedelic: Analyst initiates Definium, Helus with Buy ratings